Key Products And Themes: 3Q Pharma Results Previewed
This article was originally published in Scrip
Executive Summary
Earnings season is upon us. Key motifs that will recur in pharma company briefings will include recent rhetoric on drug pricing (with pharma executive likely to emphasize how they are offering real value with innovative therapies); the threat – or for many, such as Amgen, Pfizer or Boehringer Ingelheim, the opportunity – of biosimilars given that a slew of blockbuster monoclonal antibodies are reaching or nearing loss of exclusivity; and the negative impact of currency trends on US dollar-reporting firms' sales and earnings. The perennial favorite of analyst question time, M&A intentions, will surely rear its head more than once, too.
You may also be interested in...
China Still Alluring? AZ, Pfizer Feel COVID Pinch, New Pricing Scheme Clouds Outlook
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
QUOTED. 6 August 2020. Department of Health and Social Care.
The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.
Need a specific report? 1000+ reports available
Buy Reports